1. Home
  2. HL vs VTRS Comparison

HL vs VTRS Comparison

Compare HL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hecla Mining Company

HL

Hecla Mining Company

HOLD

Current Price

$17.84

Market Cap

12.1B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$15.11

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HL
VTRS
Founded
1891
1961
Country
United States
United States
Employees
1865
30000
Industry
Precious Metals
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
17.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HL
VTRS
Price
$17.84
$15.11
Analyst Decision
Buy
Buy
Analyst Count
8
4
Target Price
$21.13
$13.50
AVG Volume (30 Days)
10.8M
8.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
0.09%
3.21%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$4.92
$4.41
Revenue Next Year
N/A
$1.96
P/E Ratio
$44.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$8.19
52 Week High
$34.17
$16.47

Technical Indicators

Market Signals
Indicator
HL
VTRS
Relative Strength Index (RSI) 41.54 65.82
Support Level $16.05 $12.90
Resistance Level $18.12 $15.22
Average True Range (ATR) 0.66 0.40
MACD -0.07 0.11
Stochastic Oscillator 21.52 93.78

Price Performance

Historical Comparison
HL
VTRS

About HL Hecla Mining Company

Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: